Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02988986
Title TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.

estrogen-receptor positive breast cancer


Sapanisertib + Tamoxifen

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.